OMNIBUS INCENTIVE PLAN (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of Total Long-Term Incentive Program Expense, Net of Forfeitures |
The total long-term incentive program expense, net of forfeitures, is detailed in the following table: | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Options | $ | 15 | | | $ | 106 | | | $ | 54 | | | $ | 194 | | | RSUs | 1,295 | | | 682 | | | 2,178 | | | 1,264 | | | RSAs | 708 | | | 360 | | | 1,316 | | | 869 | | | SARs | (948) | | | 380 | | | (1,515) | | | 324 | | | Total | $ | 1,070 | | | $ | 1,528 | | | $ | 2,033 | | | $ | 2,651 | |
As of June 30, 2026, total unrecognized compensation expense and the applicable weighted average period for that expense to be recognized is as follows: | | | | | | | | | | | | | Unrecognized compensation | | Weighted average period | | Options | $ | 270 | | | 0.4 years | | RSUs | 9,931 | | | 4.9 years | | RSAs | 3,805 | | | 1.2 years | Total | $ | 14,006 | | | |
|
| Share-Based Represents the Total Expense Relating to Retained Pre-UK IPO Shares Recognized |
The table below represents the total expense relating to the long-term incentive program recognized in the consolidated statements of operations and comprehensive loss as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Cost of services | $ | 315 | | | $ | 1,302 | | | $ | 1,031 | | | $ | 2,165 | | | General and administrative expense | 755 | | | 226 | | | 1,002 | | | 486 | | | Total | $ | 1,070 | | | $ | 1,528 | | | $ | 2,033 | | | $ | 2,651 | |
|
| Summary of Stock Options Activity |
The following summarizes the stock option activity for the three and six months ended June 30, 2026 and 2025: | | | | | | | | | | | | | | | | | | | | | | | | | Number of Shares | | Weighted Average Exercise Price- (USD)(1) | | Weighted Average Exercise Price-(GBP) | | Weighted Average Contractual Term (in years) | | Outstanding as of December 31, 2025 | 702,002 | | $ | 11.33 | | | £ | 8.42 | | | 6.9 | | Granted | 43,987 | | 10.41 | | | 7.85 | | | 9.9 | | Exercised | — | | — | | | — | | | — | | Cancelled/Forfeited | (11,078) | | 11.38 | | | 8.58 | | | | | Outstanding as of June 30, 2026 | 734,911 | | 11.21 | | | 8.46 | | | 6.7 | | Exercisable as of June 30, 2026 | 598,016 | | 10.74 | | | 8.10 | | | 5.3 | | Vested and expected to vest as of June 30, 2026 | 734,911 | | $ | 11.21 | | | £ | 8.46 | | | 6.7 |
| | | | | | | | | | | | | | | | | | | | | | | | | Number of Shares | | Weighted Average Exercise Price- (USD)(1) | | Weighted Average Exercise Price-(GBP) | | Weighted Average Contractual Term (in years) | | Outstanding as of December 31, 2024 | 676,709 | | $ | 10.75 | | | £ | 8.60 | | | 7.8 | | Granted | 62,588 | | 11.50 | | | 8.35 | | | — | | Exercised | — | | — | | | — | | | — | | Cancelled/Forfeited | (23,897) | | 11.90 | | | 8.65 | | | — | | Outstanding as of June 30, 2025 | 715,400 | | 11.80 | | | 8.60 | | | 7.6 | | Exercisable as of June 30, 2025 | 433,392 | | 12.15 | | | 8.85 | | | — | | Vested and expected to vest as of June 30, 2025 | 715,400 | | $ | 11.80 | | | £ | 8.60 | | | 7.6 |
(1)The applicable exercise prices have been adjusted based on the applicable exchange rate of GBP to USD at the end of each period presented.
|
| Schedule of Activity in the Company's Non-Vested RSUs and RSAs |
Activity in the Company's non-vested RSUs was as follows for the three and six months ended June 30, 2026 and 2025, respectively: | | | | | | | | | | | | | Number of RSUs | | Weighted Average Grant Date Fair Value | | Nonvested as of December 31, 2025 | 991,732 | | $ | 7.70 | | | Granted | 669,879 | | 9.10 | | | Vested | (435,839) | | 7.76 | | | Cancelled/Forfeited | (19,480) | | 8.69 | | | Nonvested as of June 30, 2026 | 1,206,292 | | $ | 8.85 | | | | | | | Nonvested as of December 31, 2024 | 869,330 | | 7.00 | | | Granted | 498,532 | | 8.75 | | | Vested | (285,804) | | 7.00 | | | Cancelled/Forfeited | (27,600) | | 7.60 | | | Nonvested as of June 30, 2025 | 1,054,458 | | $ | 7.65 | |
Activity in the Company's non-vested RSAs was as follows: | | | | | | | | | | | | | Number of RSAs | | Weighted Average Grant Date Fair Value | | Nonvested as of December 31, 2025 | 408,284 | | $ | 7.91 | | | Granted | 302,080 | | 10.45 | | | Vested | (195,033) | | 9.45 | | | Cancelled/Forfeited | — | | — | | | Nonvested as of June 30, 2026 | 515,331 | | $ | 8.82 | | | | | | | Nonvested as of December 31, 2024 | 479,491 | | 6.15 | | | Granted | 195,588 | | 9.45 | | | Vested | (134,177) | | 7.15 | | | Cancelled/Forfeited | (61,005) | | 5.65 | | | Nonvested as of June 30, 2025 | 479,897 | | $ | 9.30 | |
|
| Schedule of Fair Value of the SARs Calculation |
The fair value of the SARs was calculated as follows as of: | | | | | | | | | | | | | June 30, 2026 | | December 31, 2025 | | Estimated dividend yield | 3.0 | % | | 4.0 | % | | Expected stock price volatility | 45.0 | % | | 42.0 | % | | Risk-free interest rate | 4.1% to 4.2% | | 3.5% to 3.6% | | Expected life of instrument (in years) | 1.4 to 2.8 years | | 1.9 to 3.3 years | | Weighted average fair value per share | $ | 1.64 | | | $ | 6.60 | |
|
| Schedule of Stock Appreciation Right, Activity |
Activity in the Company's SARs was as follows for the year ended June 30, 2026 and year ended December 31, 2025: | | | | | | | | | | | | | Number of Shares | | Weighted Average Exercise Price | | Outstanding as of December 31, 2024 | 341,000 | | $ | 8.05 | | | Granted | — | | — | | | Exercised | — | | — | | | Cancelled/Forfeited | (30,000) | | 8.98 | | | Outstanding as of December 31, 2025 | 311,000 | | $ | 8.97 | | | Granted | — | | — | | | Exercised | (30,000) | | (8.85) | | | Cancelled/Forfeited | (10,000) | | (8.83) | | | Outstanding as of June 30, 2026 | 271,000 | | 8.79 | | | Exercisable as of June 30, 2026 | 269,333 | | 8.84 | | | Vested and expected to vest as of June 30, 2026 | 271,000 | | $ | 8.79 | |
|